Skip to content

Author

Linyu Yang

We have 3 of 41 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Targeting PIM kinases in cancer and inflammatory disorders: From mechanisms to clinical translation.

Proviral integration site for Moloney murine leukemia virus (PIM) kinase family (PIM1, PIM2, and PIM3) comprises constitutively active serine/threonine kinases that function as proto-oncogenic and immune-inflammatory signaling nodes. In cancer, PIM kinases promote tumor growth, therapeutic resistance, and immune microe...

Qing-Yan Li, Q. Qiu, Lin Ding et al. · 0 citations
Aug 2026

Optimization of a Series of Novel 1H-Pyrrolo[3,2-c]pyridine-Based USP1 Inhibitors with Potent In Vivo Antitumor Activity.

USP1, a deubiquitinating enzyme critical for DNA damage repair, represents a promising therapeutic target for cancers. In this study, we employed scaffold hopping to design and synthesize a series of 1H-pyrrolo[3,2-c]pyridine-based USP1 inhibitors. Among these, the lead compound 38a displayed robust enzymatic and cellu...

Tao Yang, Xue Cui, Qing-Yan Li et al. · 0 citations
Aug 2026

Discovery, Synthesis, and Biological Evaluation of 1,3,4,5-Tetrahydro-6H-pyrano[4,3-c]isoquinolin-6-one Derivatives as Novel and Highly Selective PARP1 Inhibitors.

(R)-A17, a novel, highly selective PARP1 inhibitor featuring a unique tricyclic scaffold, is developed and established as a promising candidate and the design strategy for the next-generation PARP1-targeted therapy is validated.

Zhongning Guo, Rongrong Sun, Lin-Yu Yang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.